- Contact us: 01476 247 007
3rd September 2020
On Monday 1 September 2020, the MHRA released an update to the guidance on pharmacovigilance post-transitional period and I am sure we all heard the emails […]
7th February 2020
There has been and still is a huge amount of confusion regarding the requirements for establishing a UK QPPV following the UK’s exit from Europe on […]
15th January 2020
Pure Drug Safety is ready to help you with your post Brexit pharmacovigilance and regulatory requirements – deal or no deal. Just call us now for […]
22nd July 2019
Yellow fever vaccine – following two fatalities – the vaccine must not be given to patients that present with a history of thymus dysfunction, or is […]
4th April 2019
Recently, (24 March 2019), the FDA have started to scrutinise the safety of breast implants, which brings into focus the importance of post-marketing surveillance in patient […]
4th April 2019
EU referral procedures for safety reasons: Just started – review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine. The review to examine existing […]
21st March 2019
TB is the world’s deadliest infectious killer. The disease is preventable and curable. Globally the TB mortality rate has reduced by 42% since 2000 (saving an […]